The Drugs for Neglected Diseases initiative (DNDi) participated in several activities at the XIIth International Congress of Parasitology (ICOPA) 2010: the organisation of two symposia, (Malaria and Drug Discovery), as well as a preview of the documentary “1$ for 1 life“.
DNDi Symposia
• Tuesday, August 17, 2010 (10:30am—12:00)
Artesunate-based combination treatments for malaria
Chairs: Dr. Visweswaran Navaratman (DNDi Malaysia) and Dr. Bernhards Ogutu (Kenya Medical Research Institute)
(click on the link to read the abstract)
Speakers:
Dr. Elisabeth Ashley (Imperial College NHS Trust, UK): Artesunate-mefloquine: past, present and future
Dr. Stephan Duparc (Medicines for Malaria Venture, Switzerland): Pyramax® (pyronaridine/artesunate), tablet or paediatric sachet, versus Coartem® (artemether/lumefantrine), tablet or crushed tablet, in patients with acute uncomplicated Plasmodium falciparum malaria: results of two pivotal phase III studies
Dr. François Bompart (sanofi-aventis, France): ASAQ: New data and post registration study plan progress
Prof. Umberto d’Alessandro (Prince Leopold Institute of Tropical Medicine, Belgium): Dihydroartemisinin-piperaquine: an update
• Tuesday, August 17, 2010 (1:45pm—3:15pm)
The DNDi model for drug discovery programs of neglected diseases
Chairs: Prof. Simon Croft (London School of Hygiene & Tropical Medicine, UK) and Prof. Susan Charman (Monash Institute of Pharmaceutical Sciences, Australia)
Speakers:
Dr. Robert Don (DNDi, Switzerland): The DNDi model: from screening through lead optimization programmes to preclinical candidates
Dr. Shing Chang (DNDi, Switzerland): Fexinidazole: a new oral drug for the treatment of human African trypanosomiasis
Dr. Bob Jacobs (Scynexis, USA): SCYX 7158: chemistry background and new findings
Dr. Denis Martin (DNDi, Switzerland): Identification and development of New Chemical Entities to treat visceral leishmaniasis: a bumpy road
Dr. Martine Keenan (Epichem, Australia): Novel compounds for the treatment of Chagas disease
Dr. Lucio Freitas-Junior (Institut Pasteur Korea, Rep. South Korea): Phenotypic high-throughput screening for kinetoplastids
